Literature DB >> 22189290

Altered serotonergic function may partially account for behavioral endophenotypes in steroid sulfatase-deficient mice.

Simon Trent1, Tommaso Cassano, Gaurav Bedse, Obah A Ojarikre, Trevor Humby, William Davies.   

Abstract

The X-linked gene STS encodes the steroid hormone-modulating enzyme steroid sulfatase. Loss-of-function of STS, and variation within the gene, have been associated with vulnerability to developing attention deficit hyperactivity disorder (ADHD), a neurodevelopmental condition characterized by inattention, severe impulsivity, hyperactivity, and motivational deficits. ADHD is commonly comorbid with a variety of disorders, including obsessive-compulsive disorder. The neurobiological role of steroid sulfatase, and therefore its potential role in ADHD and associated comorbidities, is currently poorly understood. The 39,X(Y)*O mouse, which lacks the Sts gene, exhibits several behavioral abnormalities relevant to ADHD including inattention and hyperactivity. Here, we show that, unexpectedly, 39,X(Y)*O mice achieve higher ratios than wild-type mice on a progressive ratio (PR) task thought to index motivation, but that there is no difference between the two groups on a behavioral task thought to index compulsivity (marble burying). High performance liquid chromatography analysis of monoamine levels in wild type and 39,X(Y)*O brain tissue regions (the frontal cortex, striatum, thalamus, hippocampus, and cerebellum) revealed significantly higher levels of 5-hydroxytryptamine (5-HT) in the striatum and hippocampus of 39,X(Y)*O mice. Significant correlations between hippocampal 5-HT levels and PR performance, and between striatal 5-HT levels and locomotor activity strongly implicate regionally-specific perturbations of the 5-HT system as a neurobiological candidate for behavioral differences between 40,XY and 39,X(Y)*O mice. These data suggest that inactivating mutations and functional variants within STS might exert their influence on ADHD vulnerability, and disorder endophenotypes through modulation of the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189290      PMCID: PMC3306888          DOI: 10.1038/npp.2011.314

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

1.  Effect of paroxetine on marble-burying behavior in mice.

Authors:  K Shinomiya; Y Fujii; Y Sugimoto; N Azuma; S Tokunaga; K Kitazumi; C Kamei
Journal:  Methods Find Exp Clin Pharmacol       Date:  2005-12

2.  Effect of methylphenidate on motivation in children with attention-deficit/hyperactivity disorder.

Authors:  John J Chelonis; Teresa A Johnson; Sherry A Ferguson; Kimberly J Berry; Brian Kubacak; Mark C Edwards; Merle G Paule
Journal:  Exp Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.157

3.  Assessing motivation in children using a progressive ratio task.

Authors:  John J Chelonis; Claire R Gravelin; Merle G Paule
Journal:  Behav Processes       Date:  2011-04-17       Impact factor: 1.777

Review 4.  Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates.

Authors:  Noa Albelda; Daphna Joel
Journal:  Neurosci Biobehav Rev       Date:  2011-04-15       Impact factor: 8.989

5.  Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion.

Authors:  Tommaso Cassano; Silvana Gaetani; Maria Grazia Morgese; Teresa Macheda; Leonardo Laconca; Pasqua Dipasquale; Juan Taltavull; Toni S Shippenberg; Vincenzo Cuomo; Gabriella Gobbi
Journal:  Neurochem Res       Date:  2009-02-20       Impact factor: 3.996

6.  Identifying molecular substrates in a mouse model of the serotonin transporter x environment risk factor for anxiety and depression.

Authors:  Valeria Carola; Giovanni Frazzetto; Tiziana Pascucci; Enrica Audero; Stefano Puglisi-Allegra; Simona Cabib; Klaus-Peter Lesch; Cornelius Gross
Journal:  Biol Psychiatry       Date:  2007-10-22       Impact factor: 13.382

Review 7.  Converging methods in studying attention-deficit/hyperactivity disorder: what can we learn from neuroimaging and genetics?

Authors:  Sarah Durston
Journal:  Dev Psychopathol       Date:  2008

8.  Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder.

Authors:  Umathe S N; Vaghasiya J M; Jain N S; Dixit P V
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-06-21       Impact factor: 5.067

9.  Steroid sulfatase-deficient mice exhibit endophenotypes relevant to attention deficit hyperactivity disorder.

Authors:  Simon Trent; Alison Dennehy; Heather Richardson; Obah A Ojarikre; Paul S Burgoyne; Trevor Humby; William Davies
Journal:  Psychoneuroendocrinology       Date:  2011-07-01       Impact factor: 4.905

10.  Contiguous gene syndrome due to an interstitial deletion in Xp22.3 in a boy with ichthyosis, chondrodysplasia punctata, mental retardation and ADHD.

Authors:  Fortunato Lonardo; Giancarlo Parenti; Daniela Varela Luquetti; Ida Annunziata; Matteo Della Monica; Lucia Perone; Manuela De Gregori; Orsetta Zuffardi; Nicola Brunetti-Pierri; Generoso Andria; Gioacchino Scarano
Journal:  Eur J Med Genet       Date:  2007-05-21       Impact factor: 2.708

View more
  16 in total

Review 1.  Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD).

Authors:  June Bryan de la Peña; Irene Joy Dela Peña; Raly James Custodio; Chrislean Jun Botanas; Hee Jin Kim; Jae Hoon Cheong
Journal:  Mol Neurobiol       Date:  2017-05-22       Impact factor: 5.590

2.  Genetic and pharmacological modulation of the steroid sulfatase axis improves response control; comparison with drugs used in ADHD.

Authors:  William Davies; Trevor Humby; Simon Trent; Jessica B Eddy; Obah A Ojarikre; Lawrence S Wilkinson
Journal:  Neuropsychopharmacology       Date:  2014-05-20       Impact factor: 7.853

3.  Biological mechanisms associated with increased perseveration and hyperactivity in a genetic mouse model of neurodevelopmental disorder.

Authors:  Simon Trent; Rachel Dean; Bonnie Veit; Tommaso Cassano; Gaurav Bedse; Obah A Ojarikre; Trevor Humby; William Davies
Journal:  Psychoneuroendocrinology       Date:  2012-12-29       Impact factor: 4.905

4.  Aberrant Monoaminergic System in Thyroid Hormone Receptor-β Deficient Mice as a Model of Attention-Deficit/Hyperactivity Disorder.

Authors:  Masanori Ookubo; Miyuki Sadamatsu; Atsushi Yoshimura; Satoru Suzuki; Nobumasa Kato; Hideto Kojima; Naoto Yamada; Hirohiko Kanai
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-22       Impact factor: 5.176

5.  Altered brain gene expression but not steroid biochemistry in a genetic mouse model of neurodevelopmental disorder.

Authors:  Simon Trent; Jonathan P Fry; Obah A Ojarikre; William Davies
Journal:  Mol Autism       Date:  2014-03-06       Impact factor: 7.509

6.  Behavioural and Psychiatric Phenotypes in Men and Boys with X-Linked Ichthyosis: Evidence from a Worldwide Online Survey.

Authors:  Sohini Chatterjee; Trevor Humby; William Davies
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

7.  A pharmacological mouse model suggests a novel risk pathway for postpartum psychosis.

Authors:  Trevor Humby; Ellen S Cross; Lauren Messer; Silvia Guerrero; William Davies
Journal:  Psychoneuroendocrinology       Date:  2016-09-28       Impact factor: 4.905

8.  Medical and neurobehavioural phenotypes in male and female carriers of Xp22.31 duplications in the UK Biobank.

Authors:  Samuel J A Gubb; Lucija Brcic; Jack F G Underwood; Kimberley M Kendall; Xavier Caseras; George Kirov; William Davies
Journal:  Hum Mol Genet       Date:  2020-10-10       Impact factor: 6.150

Review 9.  A new molecular risk pathway for postpartum mood disorders: clues from steroid sulfatase-deficient individuals.

Authors:  Harish Thippeswamy; William Davies
Journal:  Arch Womens Ment Health       Date:  2020-11-20       Impact factor: 3.633

Review 10.  Transgenic mouse models for ADHD.

Authors:  Damiana Leo; Raul R Gainetdinov
Journal:  Cell Tissue Res       Date:  2013-05-17       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.